Our study here verifies the protective role of the TRIOL- and NR4A3-related mechanism in VEC and the pulmonary endothelium against OGD-R/hypoxia injury, supporting the idea that TRIOL serves as a candidate agent for the treatment of ALI. The gene discussed is NR4A3; the disease is acute respiratory distress syndrome.